Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recruiting Adolescent and Young Adult Cancer Survivors for Patient-Reported Outcome Research: Experiences and Sample Characteristics of the SURVAYA Study.
Vlooswijk C, Poll-Franse LVV, Janssen SHM, Derksen E, Reuvers MJP, Bijlsma R, Kaal SEJ, Kerst JM, Tromp JM, Bos MEMM, Hulle TV, Lalisang RI, Nuver J, Kouwenhoven MCM, van der Graaf WTA, Husson O. Vlooswijk C, et al. Among authors: bos memm. Curr Oncol. 2022 Jul 29;29(8):5407-5425. doi: 10.3390/curroncol29080428. Curr Oncol. 2022. PMID: 36005166 Free PMC article.
Patient-Reported Outcomes of Accelerated Aging: A Novel Approach to Investigate Second Cancer Risk in Adolescent and Young Adult (18-39 Years) Cancer Survivors.
van der Meer DJ, Zevenbergen S, Vlooswijk C, Bijlsma RM, Kaal SEJ, Kerst JM, Tromp JM, Bos MEMM, van der Hulle T, Lalisang RI, Nuver J, Kouwenhoven MCM, van der Graaf WTA, Husson O. van der Meer DJ, et al. Among authors: bos memm. Oncologist. 2024 Apr 4;29(4):e526-e534. doi: 10.1093/oncolo/oyad307. Oncologist. 2024. PMID: 37995309 Free PMC article.
Exploring the interconnectedness between health-related quality of life factors among long-term adolescent and young adult cancer survivors (AYAs): a network analysis.
Bootsma TI, van de Wal D, Vlooswijk C, Roos DC, Drabbe C, Tissier R, Bijlsma RM, Kaal SEJ, Kerst JM, Tromp JM, Bos MEMM, van der Hulle T, Lalisang RI, Nuver J, Kouwenhoven MCM, van der Graaf WTA, Janssen SHM, Husson O. Bootsma TI, et al. Among authors: bos memm. Support Care Cancer. 2024 Jan 13;32(2):104. doi: 10.1007/s00520-023-08295-0. Support Care Cancer. 2024. PMID: 38217712 Free PMC article.
Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study.
Eijkelboom AH, de Munck L, Vrancken Peeters MTFD, Broeders MJM, Strobbe LJA, Bos MEMM, Schmidt MK, Guerrero Paez C, Smidt ML, Bessems M, Verloop J, Linn S, Lobbes MBI, Honkoop AH, van den Bongard DHJG, Westenend PJ, Wesseling J, Menke-van der Houven van Oordt CW, Tjan-Heijnen VCG, Siesling S; NABON COVID-19 Consortium and the COVID and Cancer-NL Consortium. Eijkelboom AH, et al. Among authors: bos memm. J Hematol Oncol. 2021 Apr 17;14(1):64. doi: 10.1186/s13045-021-01073-7. J Hematol Oncol. 2021. PMID: 33865430 Free PMC article.
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
Claessens AKM, Bos MEMM, Lopez-Yurda M, Bouma JM, Rademaker-Lakhai JM, Honkoop AH, de Graaf H, van Druten E, van Warmerdam LJC, van der Sangen MJC, Tjan-Heijnen VCG, Erdkamp FLG; Dutch Breast Cancer Research Group (BOOG). Claessens AKM, et al. Among authors: bos memm. Breast Cancer Res Treat. 2018 Nov;172(2):413-423. doi: 10.1007/s10549-018-4906-8. Epub 2018 Aug 18. Breast Cancer Res Treat. 2018. PMID: 30121808 Clinical Trial.
The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer.
Claessens AKM, Timman R, Busschbach JJ, Bouma JM, Rademaker-Lakhai JM, Erdkamp FLG, Tjan-Heijnen VCG, Bos MEMM; Dutch Breast Cancer Research Group (BOOG). Claessens AKM, et al. Among authors: bos memm. Breast Cancer Res Treat. 2020 Feb;179(3):677-685. doi: 10.1007/s10549-019-05495-3. Epub 2019 Nov 28. Breast Cancer Res Treat. 2020. PMID: 31782032 Free PMC article.
Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.
Claessens AKM, Erdkamp FLG, Lopez-Yurda M, Bouma JM, Rademaker-Lakhai JM, Honkoop AH, de Graaf H, Tjan-Heijnen VCG, Bos MEMM; Dutch Breast Cancer Research Group (BOOG). Claessens AKM, et al. Among authors: bos memm. Acta Oncol. 2020 Jun;59(6):713-722. doi: 10.1080/0284186X.2020.1731923. Epub 2020 Mar 6. Acta Oncol. 2020. PMID: 32141389 Clinical Trial.
31 results